Use

This panel interrogates 7 genes (FLT3, IDH1/IDH2, CEBPA, KIT, NPM1, TP53) for clinically significant mutations associated with treatment selection and/or prognosis in acute myeloid leukemia (AML). FLT3 mutations (ITDs and TKD) correlate with poor outcomes but may qualify patients for FDA‑approved targeted therapy (midostaurin). Gain‑of‑function mutations in IDH1/IDH2 are frequent in AML and associated with unfavorable prognosis; IDH inhibitors are FDA‑approved for mutated AML. CEBPA biallelic mutations suggest improved outcomes; KIT mutations indicate poorer prognosis in CBF‑AML; NPM1 mutations may predict favorable response; TP53 mutations indicate poor outcomes and complex karyotypes.